Clinical experience with pemetrexed in breast cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 2, 2006, Pages

  Martin, Miguel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; CAPECITABINE; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; HOMOCYSTEINE; LIVER ENZYME; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PURINE; PYRIMIDINE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE;

AMINO ACID BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DRUG ACTIVITY; DRUG EFFECT; DRUG ERUPTION; DRUG INDICATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SYNTHESIS; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPOTHESIS; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; EXANTHEMA; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; MUCOSITIS; NEOPLASM METASTASIS; NEUTROPENIA; TREATMENT OUTCOME; VITAMIN B 12;

EID: 32044459320     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.003     Document Type: Conference Paper

References (24)

1. G.N. Hortobagyi Treatment of breast cancer N Engl J Med 339 1998 974 984
2. L. Wiserman, C.M. Spencer Paclitaxel An update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers Drugs Aging 12 1998 305 334
3. A.T. Van Oosterom, D. Schrivers Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience Anticancer Drugs 6 1995 356 368
4. A.R. Hanauske, V. Chen, P. Paoletti Pemetrexed disodium A novel antifolate clinically active against multiple solid tumors Oncologist 6 2001 363 373
5. C. Shih, D.E. Thomton Preclinical pharmacology studies and development of a novel multitargeted antifolate, MTA (LY231514) A.L. Jackman Antifolate Drugs in Cancer Therapy 1999 Humana Press Totowa, NJ 183 201
6. V.J. Chen, J.R. Bawley, L. Gossett Activity of LY231514 against several enzymes in the folate-dependent pathways Proc Am Assoc Cancer Res 37 1996 2598 (abstr)
7. W. John, J. Picus, C. Blanke Multitargeted antifolate (pemetrexed disodium), LY231514) in patients with advanced colorectal cancer. Results from a phase II study Cancer 88 2000 1807 1813
8. X. Pivot, E. Raymond, D. Gedouin Phase II trial of MTA (multitargeted antifolate) in advanced or recurrent squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 18 1999 397a (abstr)
9. L. Paz-Ares, J. Tabernero, A. Moyano Significant activity of multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder Results of a phase II trial Ann Oncol 9 1998 292 297
10. L. Celio, E. Bajetta, L. Toffolatti Phase II trial of pemetrexed disodium administered every 21 days in patients with gastric cancer Efficacy and toxicity without and with folic acid Ann Oncol 11 2000 65 69
11. C. Niyikiza, J. Walling, D. Thornton LY231514 (MTA) Relationship of vitamin metabolite profile to toxicity Proc Am Soc Clin Oncol 17 1998 558 (abstr)
12. P. Bunn, P. Paoletti, C. Niyikiza Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/ antimetabolite Proc Am Soc Clin Oncol 20 2001 300 (abstr)
13. F. Fossella, C. Obasaju, S. Paul Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): Could vitamin supplementation affect docetaxel survival? An exploratory analysis Proc Am Soc Clin Oncol 23 2004 646 (abstr 7131)
14. G.V. Scagliotti, D.M. Shin, H.L. Kindler Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma J Clin Oncol 21 2003 1556 1561
15. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
16. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
17. D.W. Miles, I.E. Smith, R.E. Coleman A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer Eur J Cancer 37 2001 1366 1371
18. M. Martin, M. Spielmann, M. Namer Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines Ann Oncol 14 2003 1246 1252
19. M. Spielmann, M. Martin, M. Namer Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) metastatic breast cancer patients previously treated with an anthracycline and a taxane An interim analysis Clin Breast Cancer 2 2001 47 51
20. A. Llombart-Cussac, M. Theodoulou, K. Rowland A phase II trial of pemetrexed disodium (ALIMTA, LY23154) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy) Breast Cancer Res Treat 64 2000 120a (abstr 526)
21. M. Theodoulou, A. Llombart, G. Cruciani Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients with prior anthracycline or anthracenedione and taxane treatment Phase II study Proc Am Soc Clin Oncol 19 2000 130a (abstr 506)
22. R.G. Mennel, J. O'Shaughnessy, J.L. Blum Pemetrexed disodium (ALIMTA, LY231514, MTA) in advanced breast cancer (ABC) patients (pts) with prior anthracycline or anthracenedione, taxane and capecitabine treatment A phase II study Proc Am Soc Clin Oncol 20 2001 49a (abstr 194)
23. H.L. Gomez, A.R. Hanauske, S. Santillana A phase II trial of pemetrexed in previously untreated breast cancer Proc Am Soc Clin Oncol 21 2002 57a (abstr 225)
24. L.A. Hammond, L. Forero, M. Beeram Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic breast cancer Proc Am Soc Clin Oncol 22 2003 133 (abstr 532)